Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and mk-8776

gemcitabine has been researched along with mk-8776 in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (92.31)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Bhagwat, B; Davis, N; Dwyer, MP; Gu, D; Guzi, TJ; Hsieh, Y; Labroli, M; Lee, S; Liu, M; Parry, D; Paruch, K; Penaflor, E; Seghezzi, W; Shanahan, F; Taricani, L; Wang, W; Wiswell, D1
Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D1
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE1
Davis, MA; Engelke, CG; Greenson, JK; Karnak, D; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Qian, Y; Robertson, JR; Tanska, DM; Wei, D; Zhang, Q; Zhao, L1
Chung, I; Eastman, A; Hou, H; Khan, N; Montano, R; Thompson, R1
Du, G; Eastman, A; Gimi, B; Hou, H; Khan, N; Krishnamurthy Nemani, V; Montano, R; Song, R; Swartz, HM1
Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP1
Eastman, A; Sakurikar, N1
Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J1
Chen, P; Dai, CH; Jiang, Q; Lan, T; Li, J; Li, MY; Su, JY; Wang, Y; Wu, Y1
Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM1
Eastman, A; Warren, NJH1
Asano, T; Isono, M; Okubo, K; Sato, A1

Trials

1 trial(s) available for gemcitabine and mk-8776

ArticleYear
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-20, Volume: 33, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors

2015

Other Studies

12 other study(ies) available for gemcitabine and mk-8776

ArticleYear
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclic N-Oxides; Cyclin-Dependent Kinases; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Replication; Drug Screening Assays, Antitumor; Gemcitabine; Histones; Humans; Immunoblotting; Indolizines; Mice; Mice, Nude; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Pyridinium Compounds; Pyrimidines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays

2011
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

    Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine

2012
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Cancer research, 2013, Jun-15, Volume: 73, Issue:12

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan

2013
Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Aug-15, Volume: 19, Issue:16

    Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Chemoradiotherapy; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Radiation-Sensitizing Agents; Recombinational DNA Repair; Xenograft Model Antitumor Assays

2013
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
    BMC cancer, 2013, Dec-21, Volume: 13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pyrazoles; Pyrimidines; Recombinational DNA Repair; S Phase Cell Cycle Checkpoints; Tumor Burden; Xenograft Model Antitumor Assays

2013
Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.
    International journal of cancer, 2015, Apr-01, Volume: 136, Issue:7

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carbon Dioxide; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glioma; Humans; Hypoxia; Inhalation; Magnetic Resonance Imaging; Male; Mice; Oximetry; Oxygen; Oxygen Consumption; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays

2015
Will targeting Chk1 have a role in the future of cancer therapy?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-20, Volume: 33, Issue:9

    Topics: Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms; Protein Kinases; Pyrazoles; Pyrimidines

2015
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine

2016
Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
    Scientific reports, 2017, 11-08, Volume: 7, Issue:1

    Topics: A549 Cells; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Fanconi Anemia Complementation Group Proteins; Gemcitabine; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction

2017
The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:9

    Topics: Analysis of Variance; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Replication; Gemcitabine; Histones; Humans; Nucleosides; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Roscovitine; Staining and Labeling

2018
Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
    The Journal of biological chemistry, 2019, 02-08, Volume: 294, Issue:6

    Topics: Cell Cycle Proteins; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Deoxycytidine; DNA Replication; DNA, Single-Stranded; Gemcitabine; Humans; PC-3 Cells; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; S Phase Cell Cycle Checkpoints

2019
Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Scientific reports, 2021, 05-13, Volume: 11, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pyrazoles; Pyrimidines; Tumor Stem Cell Assay; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2021